MacroGenics stock has October 23 data ahead in 2026

Published on 10/15/2026 at 22:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 32.83 million on August 13, 2026. MacroGenics stock costs EUR 3.00 on October 15, 2026 at 10:54 p.m. CEST.

Scheduled data and valuation

MacroGenics plans to present MGC026 data at ESMO Congress from October 23 through October 27, 2026.
Second-quarter revenue was USD 32.83 million versus USD 59.14 million expected on August 13, 2026.
MacroGenics stock costs EUR 3.00 at Lang & Schwarz on October 15, 2026 at 10:54 p.m. CEST.
MacroGenics had a market capitalization of USD 214.7 million on October 15, 2026.

MGNX, US5560991094, Illustration mit AI erstellt.

MacroGenics (ISIN US5560991094) has a scheduled clinical-data date on the calendar: the company plans to present MGC026 information at the European Society for Medical Oncology Congress in Madrid from October 23 through October 27, 2026, according to Simply Wall St. The planned appearance gives investors a dated checkpoint for the antibody-drug conjugate pipeline. MacroGenics stock costs EUR 3.00 at Lang & Schwarz on October 15, 2026 at 10:54 p.m. CEST.

Revenue sets the next comparison

MacroGenics reported USD 32.83 million of revenue for the second quarter of 2026, while the consensus estimate was USD 59.14 million, according to MarketBeat. Revenue was 44.47 percent below that estimate. The same report lists actual earnings per share of USD 0.31 against a consensus loss of USD 0.08 for the quarter.

Price position on October 15

The latest US quote was USD 3.37 on Nasdaq at 4:00 p.m. Eastern Time on October 15, 2026, while the euro quotation was EUR 3.00 at Lang & Schwarz later in the Berlin session. The finance data also places the 52-week range at USD 1.29 to USD 5.08. MacroGenics is 33.64 percent below the upper end of that range and 132.56 percent above the lower end.

On October 15, 2026, MacroGenics announced that the first patient had been dosed in the Phase 1 study of MGC030, according to TradingView News. The study is designed to enroll up to 54 participants during dose escalation.

Valuation and peer lines

MacroGenics had a market capitalization of USD 214.7 million and a negative price-to-earnings ratio of 15.32 on October 15, 2026. Its dividend yield was zero, and the company remains a clinical-stage biotechnology business.

As of October 15, 2026, the comparison figures were:

Comparison with peers

MGNX: P/E -15.32, market capitalization USD 214.7 million
Immunocore (Nasdaq, USD): plus 4.02 percent, P/E -154.91, market capitalization USD 1.5 billion
Fate Therapeutics (Nasdaq, USD): minus 0.77 percent, P/E -1.83, market capitalization USD 224.4 million

Upcoming dates and price

The next dated pipeline event is the ESMO Congress presentation scheduled for October 23 through October 27, 2026. The latest Nasdaq quote was USD 3.37 on October 15, 2026 at 4:00 p.m. Eastern Time, while the Lang & Schwarz euro quote was EUR 3.00 on October 15, 2026 at 10:54 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of MacroGenics stock.